The myeloproliferative sarcoma virus not only transforms fibroblasts but also causes extensive expansion of the hematopoietic stem cell compartment on infection of adult mice. Similar to the Moloney sarcoma virus, it carries the mos oncogene. Moloney sarcoma virus, however, does not induce myeloproliferation and leukemia in adult mice. The difference between the two viruses was explored by using their molecularly cloned genomes and the cellular mos oncogene to construct recombinant genomes. It was shown that the U3 region of the viral long terminal repeat (LTR) has a decisive function in determining the target cell specificity of the myeloproliferative sarcoma virus. Any mos gene, whether of cellular or viral origin, is sufficient in conjunction with the proper LTR to induce myeloproliferation. Our results indicate that the pathogenicity of acutely transforming viruses is determined not only by the oncogene but also by sequences in the viral LTR.
The myeloproliferative sarcoma virus (MPSV) is a member of the Moloney murine sarcoma virus (Mo-MuSV) family of replication-defective RNA tumor viruses. It is unique in that not only does it induce efficient fibroblast transformation in vitro and cause sarcomas on intramuscular injection of adult mice similar to Mo-MuSV, but also it causes extensive hematopoietic changes in vivo, including proliferation of late erythroid precursor cells, hematopoietic stem cells, and granulocyte-macrophage precursor cells (1) (2) (3) . In vitro stimulation of the proliferation of erythroid early precursor cells (BFU-E), myeloid precursor cells (CFU-C), and stem cells (CFU-S) has also been observed (4, 5) .
Biological cloning ofthe defective MPSV component ofthe MPSV/Moloney murine leukemia helper virus (Mo-MuLV) complex leading to nonproducer rat NRK cells (1) and subsequent molecular cloning (6) of MPSV allowed initial molecular comparison with other Mo-MuSV variants. MPSV has no apparent novel cellular sequences or striking rearrangements to account for its unique pathogenicity. It consists of sequences derived solely from either the MoMuLV helper virus or the cellular mos oncogene (c-mos) (6) (7) (8) , as do the other Mo-MuSV variants (9, 10) .
On the basis of restriction enzyme analysis (6) and partial sequence data (8) , three hypotheses can be formulated that might explain the dual oncogenicity of MPSV:
(i) Altered mos protein. Due to a single nucleotide deletion at the 5' junction of the helper and oncogene sequences, MPSV encodes for an amino-terminal-truncated mos protein (p34), as compared to the env/mos fusion protein (p37) of Mo-MuSV that has been detected and implicated as the transforming protein in fibroblasts (11) (12) (13) . In addition to the loss at the amino terminus, random single-base mutations have occurred in the MPSV mos coding region. These Universitat Hamburg, Martinistrasse 52, 2000 Hamburg 20,  changes, acting alone or in concert, could have altered the structure of the mos protein sufficiently to gain an increased transformation capacity. It can also be speculated that, as the MPSV mos amino acid sequence resembles c-mos more closely than does Mo-MuSV mos, perhaps the transformation of hematopoietic stem cells is a property of the unaltered c-mos protein that had been lost through alteration by the Mo-MuSV family.
(ii) Interaction of other protein(s) with the transforming protein. Due to a frameshift in the env region between mos and the 3' long terminal repeat (LTR), MPSV could encode a novel peptide designated p15ER'. This hypothetical peptide could be interacting with the transforming protein, thereby altering its target specificity.
(iii) Altered enhancer structure of the virus. It could be envisaged that the type of disease induced by the oncogene is not a function of the oncogene itself but rather of the different cell type(s) most compatible with the particular enhancer structure of the infecting virus. Recent work in other laboratories has suggested that cell target specificity is to some degree determined by the putative enhancer region of the LTR (14) . Random point mutations have occurred in the LTR sequences of all the Mo-MuSV variants. The MPSV LTR has diverged to a lesser degree from the Mo-MuLV LTR as compared to the LTRs of other variants.
To determine which sequences in the MPSV genome could explain its unique pathogenesis through altered target cell specificity, recombinants were constructed with various Mo-MuSV sequences and the c-mos oncogene. (21) at a concentration of 400 ,tg/ml.
MATERIALS AND METHODS
To rescue infectious viral particles, three cellular clones of each recombinant were superinfected with Friend-MuLV helper virus from line 643/22N (7). Genomic DNA from these clones was subjected to Southern blot analysis (22) . GeneScreen Plus filters (New England Nuclear) were hybridized according to the suppliers' recommendations to a 32P-labeled c-mos probe (pmsl).
Biological Activity in the Mouse. Spleen focus formation and fibroblast focus formation were assayed as described (1) . Serial 1:5 dilutions of virus-containing tissue culture supernatant were injected into DBA/2J mice, six mice for each dilution. Spleen weight and number of spleen foci of three mice for each dilution were determined 16 days after injection and these two quantities were determined for the other three mice 31 days after injection.
RESULTS
Construction of Recombinant Genomes. The purpose of our work was to define the sequences of MPSV that are responsible for transformation of cells of the hematopoietic system. Our approach was to construct recombinants between MPSV (6), Mo-MuSV (HT-1 and ml variants) (16) , and the c-mos oncogene (15) to establish what differences determine the altered target cell specificity of MPSV.
To generate recombinant genomes, viral plasmids were digested with restriction enzymes and appropriate fragments were ligated, using common sites, when possible, to minimize disruption of the translational reading frame. Deletion of the mos gene results in a virus that does not transform fibroblasts. A neomycin-resistance gene (21) was introduced into this virus to permit selective survival of cells containing such virus genomes, which are morphologically indistinguishable from normal fibroblasts. The strategy for the construction of the recombinants is outlined in Fig. 1 Spleen focus formation in mice was used as the criterion for hematopoietic transformation. Spleen focus-forming units (SFFU) were standardized against fibroblast focus-forming units (FFU). The ratio of SFFU to FFU normally observed with cloned MPSV pC663 was 0.05-0.15 (6) .
(i) Recombinants with mos of different origin. The first recombinant, pCM61, was made by linking the 5' half of pml (Mo-MuSV), including the 5' LTR and the gag gene, to the 3' half of MPSV, including the partially deleted pol gene (Apol), the mos gene, and the 3' LTR, using the common Bgl II site (Figs. 1 and 2) . Hence, in the infectious viral particles generated by this recombinant, the virus contains a hybrid LTR; the U3 and U5 regions are derived from MPSV and ml, respectively (23 (8) and MSV-124 (24) has detected an AUG codon 3' to the mos gene in the reading frame of the residual pl5E protein and putative R protein of Mo-MuLV (25) . Due to a nucleotide deletion in MPSV in this region, a unique peptide, designated piSER', potentially could be translated-29 amino acids derived from the 'id-frame sequences of pi5E and 21 out-of-frame sequences of the R protein. This putative peptide would still contain the highly hydrophobic carboxyl terminus of the pi5E peptide, which is also present in the gp52 protein of Friend spleen focusforming virus (26) . All above-mentioned MPSV recombinants that caused spleen focus formation in adult mice had the appropriate sequences to code for the hypothetical peptide. To eliminate the possibility that such a novel peptide could be exerting independent effects or interacting with the mos protein, recombinant pC615 was constructed, deleting the potential start codon and the 5' end of the piSER' coding region (Fig. 1) . Inoculation of mice with tissue culture supernatant containing recombinant pC615 showed no significant change in the biological activity compared to wildtype MPSV (Table 1) .
pC6M-neo was constructed by deleting the central part of the mos gene in pC663 neo, a neomycin-resistant derivative of MPSV that carries the prokaryotic gene for aminoglycosyltransferase (18) , leaving 72 in-frame nucleotides upstream to the first Pst I site and 58 out-of-frame nucleotides downstream to the fourth Pst I site of the mos gene (Fig. 1) . A UAG stop codon exists (8) A more detailed analysis of mice infected with pC6M-neo revealed that at day 16 their spleen weight increased to about 0.3 g as compared to 0.17 g of normal DDDS mice and 0.5-1 g of mice infected with a similar amount of wild-type MPSV. However, in contrast to mice infected with wild-type MPSV and molecularly cloned MPSV (pC663), spleen weight of mice infected with pC6M-neo decreased continuously after day 16, (Fig. 1) . It was found that all viruses tested did contain the predicted structure, as indicated by the length of the two restriction fragments (not shown). The viruses that were subjected to (6) . In addition to causing in vitro fibroblast transformation similar to Mo-MuSV, MPSV also causes transformation of hematopoietic stem cells and extensive leukemic changes, including spleen focus formation, upon injection into susceptible adult mice (1) . In this work, we have used recombinant viral genomes to localize the sequences that impart dual oncogenicity to MPSV and are altered or absent in Mo-MuSV.
Other acute leukemia viruses have been reported that transform both hematopoietic cells and fibroblasts in vitro and induce rapid leukemias in vivo. These include the avian erythroblastosis virus (AEV) (27) , the avian myelocytoma viruses (MC29, MH2) (28), the Abelson murine leukemia virus (Ab-MuLV) (29, 30) , the Kirsten and Harvey murine sarcoma viruses (Ki-MSV and Ha-MSV, respectively) (31) , and the related AF-1 virus (32) . All harbor at least one oncogene that has been implicated in transformation. Due to the polypotent oncogenesis of these viruses, it had been previously speculated that more than one protein was being expressed by the oncogenes (33) or that two oncogenes were present, as is the case in AEV (34, 35) or MH2 (36, 37) . However, in all of the above-cited retroviruses, except AEV and MH2, only one known protein product has been identified (33) . In the case of AEV, in which two oncogene products have been identified [p75 (gag-erbA) and gp65 (erbB)], recent work has indicated that the v-erbB gene alone is sufficient to transform both fibroblasts and erythroblasts (38) .
MPSV also contains only one known oncogene, and besides the p72 gag-related polyprotein no other protein products have been detected (49) . Indeed, MPSV completely loses its transformation capacity when sequences of the mos gene are removed, as in pC6M neo, indicating that the mos oncogene is necessary for transformation. Temperaturesensitive mutants of MPSV support the hypothesis of a single transforming protein, as both hematopoietic and fibroblast transforming properties of MPSV are blocked at nonpermissive temperatures (39) .
An acute erythroproliferative disease could be induced in mice by a recombinant virus constructed from the avian Rous sarcoma virus (RSV) src gene, when inserted into the MuLV env region in a manner analogous to MPSV (40) . Such a dramatic change in the species specificity and pathological effects of the oncogene brought about by the new viral genome suggests that, insofar as target cell specificity is concerned, some other viral structure plays an important role.
Data on recombinants pCH61, pCH62, pCB61, and pCLS3 in conjunction with the results discussed above demonstrate that the LTR region is the decisive element in determining the target cell specificity of MPSV. Hybrid virus pCM61, containing only the U3 region of MPSV, defines further this function to that region of the LTR which is known to contain structural elements for the regulation of gene expression.
The role of this essential region of the Mo-MuSV LTR in enhancement of transformation has been pointed out earlier (41) . Changes in the LTR have also been found responsible for accelerating leukemogenicity induced by MuLV (42, 43) . One part of the tandemly repeated sequence located in the U3 region of the viral LTR was identified as a transcriptional enhancer element in Mo-MuSV (15, 44, 45) . Furthermore, differences in the tandem repeats of murine leukemia viruses have also been suggested as the source of the different tissue tropisms of various virus strains (42, 43, 46, 47 The action of MPSV in specifically transforming hematopoietic cells as well as fibroblasts is thus caused by the interaction of the mos oncogene and the MPSV LTR. Fine structurefunction analysis of the LTR should enable us to specify the region of U3 that is required for acute leukemogenesis due to expansion of the target cell range.
